List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.

  1. SYSTEMIC RADIONUCLIDE THERAPY TARGETED TO VEGF RECEPTORS IN TUMOR VASCULATURE

    SBC: SIBTECH, INC.            Topic: NCI

    The overall goal of this collaborative project between SibTech Inc PI Backer J and Johns Hopkins University PI Pomper M is clinical development of efficient and cost effective anti angiogenic Lu radiopharmaceutical scV Lu for VEGF receptor mediated targeting of angiogenic tumor vasculature Current very expensive anti angiogenic compounds induce transient regression of tumor vascula ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. IGF OT IGF BASE AWARD STANDARDIZED RECHARGEABLE ELECTRONIC NICOTINE DELIVERY SYSTEM POP MARCH THROUGH NOVEMBER N DA EXTEND THE PERIOD OF PERFORMANCE FOR NO ADDITIONAL

    SBC: NJOY Inc.            Topic: NIDA

    Not Available

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. IGF OT IGF Topic Phase I SBIR Predictive Biomarkers of Adverse Reactions to Prostate Cancer Radiotherapy

    SBC: L2 DIAGNOSTICS, LLC            Topic: NCI

    Not Available

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. IGF OT IGF Topic Phase I SBIR Defining normal tissue and tumor biomarkers of radiosenstivity to detect treatment

    SBC: MIRA DX, Inc.            Topic: NCI

    Not Available

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Engineering a phosphotyrosyl-tRNA Synthetase

    SBC: AXIOMX INC            Topic: 300

    DESCRIPTION provided by applicant Although tyrosine phosphorylation is an important controlling element in cell signaling no tRNA suppressor for phosphotyrosine pTyr incorporation has yet been made We propose to use directed molecular evolution of several aminoacyl tRNA synthetases aaRSs to identify mutations that enable binding of pTyr to the aaRS Specifically ATP molecules will be att ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Rapid Monitoring and Assessment of Tubercuolosis Treatment at the Point of Care Using Breath

    SBC: NanoSynth Materials and Sensors Inc.            Topic: NHLBI

    DESCRIPTION provided by applicant Problem and Significance According to the CDC global statistics nearly of the world is infected with Tuberculosis TB In million f peopled infected lived in what is considered a high burden country Countries such as India Peru China sub Saharan Africa and others have significant regions endemic for TB particularly among the lower income ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Measuring toxicant effects on cellular function in a microarray format

    SBC: CIENCIA INC            Topic: NIEHS

    DESCRIPTION provided by applicant The EPA maintains a Toxics Release Inventory of over toxic chemicals that are disposed or released from more than industrial sites in the United States The Department of Health and Human Services and USDA maintain a list of over select agents and toxins that pose a severe risk to both human animal and plant health These compounds represent only ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Small molecule inhibitors of group II introns for treatment of fungal infections

    SBC: New England Discovery Partners, LLC            Topic: NIAID

    DESCRIPTION provided by applicant This project will result in the development of potent new inhibitors for a novel enzyme target that is specific to the metabolism of fungi and yeast the group II self splicing intron This structurally complex and highly conserved ribozyme plays a key role in RNA processing and metabolic function of lower eukaryotes but it is not present in humans and other v ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Arf6 inhibitors for the treatment of uveal melanoma

    SBC: NAVIGEN, INC.            Topic: 102

    DESCRIPTION provided by applicant Activating mutations in G proteins are the drivers of oncogenesis in numerous cancers Therefore identifying drugs that block the signaling pathways controlled by these mutations could have enormous therapeutic consequences Uveal melanoma is a prototypical G driven cancer in which about of tumors have activating mutations in one of two G encoding genes ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Targeted drug delivery to tumor microenvironment

    SBC: SIBTECH, INC.            Topic: 102

    DESCRIPTION provided by applicant The goal of this project is to test the feasibility of targeted delivery of andquot re programmingandquot liposomal drugs to tumor associated macrophages TAMs TAMs are the major component of tumor microenvironment that generally supports tumor growth and interferes with anti tumor therapy These effects are significantly mediated by about of TAMs that ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government